Full text
Earnings transcript
Read the complete earnings call transcript.
GILD
Gilead Sciences, Inc.
$139.71
-0.59
(-0.42%)
| Exchange: | NASDAQ |
| Market Cap: | 173.439B |
| Shares Outstanding: | 304.762M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – General | |||||
| CEO: | Daniel O’Day | |||||
| Full Time Employees: | 17600 | |||||
| Address: |
| |||||
| Website: | https://www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 27,116,000 | 28,754,000 | 29,443,000 |
| Gross Profit | 20,618,000 | 22,503,000 | 25,523,000 |
| EBITDA | 10,496,000 | 4,434,000 | 10,820,000 |
| Operating Income | 7,605,000 | 1,662,000 | 11,817,000 |
| Net Income | 5,665,000 | 480,000 | 8,510,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 62,125,000 | 58,995,000 | 59,023,000 |
| Total Liabilities | 39,376,000 | 39,749,000 | 36,405,000 |
| Total Stockholders Equity | 22,833,000 | 19,330,000 | 22,618,000 |
| Total Debt | 24,987,000 | 26,711,000 | 0 |
| Cash and Cash Equivalents | 6,085,000 | 9,991,000 | 0 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 8,006,000 | 10,828,000 | 10,019,000 |
| Capital Expenditure | -585,000 | -523,000 | 0 |
| Free Cash Flow | 7,421,000 | 10,305,000 | 10,019,000 |
| Net Income | 5,665,000 | 480,000 | 8,510,000 |
| Net Change in Cash | 673,000 | 3,906,000 | -2,427,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 36,980,721.082 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 39,316,401.214 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 37,980,761.508 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 12,189,975.079 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 12,959,886.583 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 12,519,618.945 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 15,469,255.512 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 16,749,782.213 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 16,017,527.362 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 7,620,950.242 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 8,102,284.882 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 7,827,037.579 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 12.760 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 13.350 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 12.330 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 10 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 3 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: Gilead Sciences reported strong financial results in the Q4 and full-year 2025 earnings call, with key metrics such as revenue and net income reflecting consistent growth. High gross profit margins (TTM) and positive free cash flow (TTM) underscore operational efficiency and financial stability.
- Strong Product Portfolio: Revenue from product segments indicates a diversified and resilient portfolio, contributing to sustained revenue streams. The earnings call highlighted successful performance in core therapeutic areas, positioning GILD as a leader in its industry.
- Healthy Liquidity Position: Balance sheet data shows substantial cash and cash equivalents alongside a favorable current ratio (TTM), indicating the ability to meet short-term obligations and fund strategic initiatives without liquidity constraints.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates GILD intrinsic value between $120.82 – $420.99 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about GILD valuation
Is Gilead Sciences, Inc. (GILD) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Gilead Sciences, Inc. (GILD) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is GILD a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GILD trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is GILD’s P/E ratio?
You can see GILD’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for GILD?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is GILD a good long-term investment?
Whether GILD fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
GILD
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.42
Trading Metrics:
| Open: | 140.22 | Previous Close: | 140.3 | |
| Day Low: | 138.64 | Day High: | 141.34 | |
| Year Low: | 93.37 | Year High: | 157.29 | |
| Price Avg 50: | 144.54 | Price Avg 200: | 124.24 | |
| Volume: | 4.579M | Average Volume: | 6.976M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeGILD full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of Gilead Sciences, ticker GILD, a heavyweight in the biopharmaceutical space. If you’re looking to understand whether this stock deserves a spot in your portfolio, stick around because we’re covering everything from financials to recent performance, valuation, and more. Let’s get started! Alright, let’s kick things off with a quick overview of what Gilead Sciences is all about. If you’re not familiar, Gilead is a…
Relevant news
